Eli Lilly Recall Push On Compounded Zepbound And Investor Risk Questions [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly has urged the FDA to recall compounded versions of its obesity drug Zepbound (tirzepatide), citing impurity and safety concerns. The company reports findings of impurities, bacterial contamination, and chemical byproducts in some compounded tirzepatide products. Lilly is asking regulators to act against unauthorized compounders that add ingredients such as vitamin B12 to tirzepatide. The move raises questions about patient safety, regulatory oversight, and the role of compounded drugs alongside approved therapies. Eli Lilly, trading as NYSE:LLY, is in the spotlight for reasons that go beyond its share price of $985.08. The stock has risen 22.0% over the past year and has returned a very large amount over 5 years, which has already drawn plenty of investor attention. This latest step on compounde
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) was downgraded by HSBC Holdings plc from "hold" to "reduce". They now have a $850.00 price target on the stock.MarketBeat
- Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day [Fortune]Fortune
- Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans [Yahoo! Finance]Yahoo! Finance
- Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/6/26 - Form PRE
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website